A drug from Regeneron Pharmaceuticals, Inc. offering a new treatment option for the neovascular form of AMD (age related macular degeneration) has been receiving vast support from the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA, urging the FDA to approve the treatment called Eylea, also known as VEGF Trap-Eye.
What’s the big deal about Eyelea versus other similar drugs like Lucentis? Both drugs are injected into the eye, yet patients on Eylea would get injections every eight weeks (following three initial doses given every four weeks). Lucentis patients on the other would get injections every four weeks.
Will this drug be another weapon available for eye-care professionals to combat a disease that commonly leads to loss of central vision? Time will tell.
